Clinical trials of four experimental treatments for Ebola in the Congo have been halted early after two of the drugs showed compelling benefits in a breakthrough against the deadly virus.
Merck & Co has begun a rolling filing in the US of its Ebola Zaire vaccine, known as V920, after the FDA said it could represent a breakthrough in treatment.
